parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including microglia; strongest in early spermatids	0.75
chemistry Open Targets	hard to drug	0.27
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 14821

IFRD1 in microglia, braak+0.24 (p 0.533) → -0.16 (p 0.672)receipt 14828
IFRD1 in dopamine neurons, braak-0.14 (p 0.714) → +0.27 (p 0.485)receipt 14829

receipt 14829: IFRD1 in dopamine neurons, braak

power: full sample +0.01 (p 0.962, n 18), 95% CI -0.46 to +0.48. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.05 (p 0.834, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.00 (p 0.990, n 18). could be the mix.
skeptic: leave-one-out range -0.11 to +0.13, sign flips 6; without severely affected donors +0.01 (p 0.962, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for IFRD1 in dopamine neurons.

case closed: nothing better to follow up.

receipt 14828: IFRD1 in microglia, braak

power: full sample +0.04 (p 0.874, n 18), 95% CI -0.43 to +0.50. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.00 (p 0.997, n 18). does not hold up.
composition: microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: -0.02 (p 0.928, n 18). could be the mix.
skeptic: leave-one-out range -0.09 to +0.20, sign flips 3; without severely affected donors +0.04 (p 0.874, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for IFRD1 in microglia.

case closed: nothing better to follow up.

loading the receipts